XOMA Co. (NASDAQ:XOMAP – Get Free Report) was the target of a significant decline in short interest during the month of February. As of February 27th, there was short interest totaling 774 shares, a decline of 37.2% from the February 12th total of 1,232 shares. Based on an average daily trading volume, of 1,226 shares, the short-interest ratio is currently 0.6 days. Based on an average daily trading volume, of 1,226 shares, the short-interest ratio is currently 0.6 days.
XOMA Price Performance
Shares of NASDAQ XOMAP opened at $25.86 on Friday. XOMA has a twelve month low of $24.96 and a twelve month high of $30.00. The business’s 50 day moving average price is $26.18 and its two-hundred day moving average price is $26.39.
About XOMA
XOMA Corporation (NASDAQ: XOMAP) is a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutic antibodies for autoimmune and inflammatory diseases. The company leverages proprietary antibody-generation technologies—including ribosome display and phage display—to identify and optimize human monoclonal antibodies with high specificity and favorable pharmacological profiles.
Its lead clinical program is an interleukin-1 beta modulator being evaluated in patients with rare and severe inflammatory conditions.
Featured Articles
- Five stocks we like better than XOMA
- The gold chart Wall Street is terrified of…
- Elon Musk already made me a “wealthy man”
- Silver paying 20% dividend. Plus 68% share gains
- Unlocked: Elon Musk’s Next Big IPO
- A personal warning from Martin Weiss (Please read)
Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.
